Mood Disorders

Adjustment disorder often goes undiagnosed after major life stressors, especially in cancer care; learn updated criteria, risks, and emerging therapies like psilocybin.

Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.

Ketogenic nutrition and insulin-targeted metabolic psychiatry may add a new tool for severe mental illness.

Learn why ketogenic metabolic therapy is a monitored medical treatment, not a fad diet, and how metabolic pathways may reshape mental health care.

Pramipexole was associated with improvement in anhedonia and apathy, and with increased physical activity in patients with mood disorders, in a placebo-controlled trial that measured both behavioral and neurophysiologic change.

Review the developments in GLP-1s in 2026.

HLP003 shows rapid, durable MADRS improvement in adjunctive MDD phase 2; phase 3 tests intermittent dosing to cut daily pill burden.

Nardin Valentin, DO, debunks common hormone therapy myths and makes the case for HRT as standard in perimenopausal and menopausal psychiatric care.

Bipolar depression does not have a single face. Through one patient’s journey, this case-based reflection explores 5 distinct presentations and how each can shape clinical recognition and treatment.

From tricyclics to esketamine, Ron Pies, MD, explains antidepressant progress and why precise diagnosis matters when treating today’s diverse depression.

Psychiatrists rebut antidepressant myths, outlining modest benefits, real but manageable risks, and why slow tapering matters for withdrawal.

Learn how clinicians manage bipolar disorder in women who may become pregnant—safer meds, contraception counseling, and relapse prevention.

COMP360 psilocybin shows rapid, durable gains in treatment‑resistant depression, as psychedelics continue to grow.

Where can vagus nerve stimulation fit into treating depression?